Drug Trial Radar · NCT07791186
Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- BMI KoreaIndustry
- Sponsor type
- Industry
- First posted
- Aug 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study evaluates the safety, tolerability, and immunogenicity of BMI2012, a self-amplifying RNA vaccine candidate targeting the SARS-CoV-2 Omicron JN .1 variant, in healthy adults aged 19 to 55 years. Participants will be enrolled sequentially into three ascending-dose cohorts and randomized within each cohort to receive a single intramuscular injection of BMI2012 or placebo. A sentinel dosing strategy with staggered administration will be used to monitor safety before enrollment of the remaining participants in each dose cohort. A Data Safety Monitoring Board (DSMB) will review safety data to determine whether enrollment may continue and to assess dose levels appropriate for further clinical development. The primary objective is to assess the safety and tolerability of BMI2012 across the dose levels studied. Secondary objectives include exploratory evaluation of humoral and cell-mediated immune responses to BMI2012 through 52 weeks after vaccination.
Conditions
- Prevention of COVID-19 Variant (Omicron JN.1)
Interventions
BMI2012 low-doseBiological
Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single low-dose intramuscular injection at Visit 2
Placebo low-doseOther
Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 low-dose
BMI2012 mid-doseBiological
Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single mid-dose intramuscular injection at Visit 2
Placebo mid-doseOther
Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 mid-dose
BMI2012 high-doseBiological
Self-amplifying RNA vaccine encoding the SARS-CoV-2 (Omicron JN.1) spike protein. Administered as a single high-dose intramuscular injection at Visit 2
Placebo high-doseOther
Normal saline solution administered as a single intramuscular injection at visit 2, volume-matched to BMI2012 high-dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events Following Investigational Product AdministrationTime frame: From administration through Day 28
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hallym University Kangnam St.Heart Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Ajou University Medical Center
Suwon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.